Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 68Gynecologic 9Thoracic 8Gastrointestinal 6Other solid neoplasm 5Lymphoid 3Genitourinary 3Tumor-Agnostic 2Sarcoma 2Other neoplasm 1

Conditions

Ovarian Neoplasms 2Stomach Neoplasms 1Liposarcoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 62Cyclophosphamide 59Radiotherapy 47Doxorubicin 36Filgrastim 26Irinotecan 24Radiation 23Gemcitabine 23fludarabine 22Magnetic Resonance Spectroscopy 20Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Fulvestrant × Sarcoma × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡